Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Non Small Cell Lung Cancer Medullary Thyroid Cancer RET Gene Mutation Metastatic Solid Tumor Advanced Solid Tumor Non-small cell lung cancer NSCLC MTC RET gene alteration Advanced non small cell lung cancer Advanced/metastatic disease lung cancer lung adenocarcinoma Advanced Solid Tumors RET gene fusion RET inhibitor SRC TPX-0046 Thyroid cancer Neoplasms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Thyroid Neoplasms
Lead Scientist at UCSD
- Lyudmila Bazhenova, MD
Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators.
- accepting new patients
- Start Date
- Completion Date
- Turning Point Therapeutics, Inc.
- Phase 1/2 research study
- Study Type
- Expecting 462 study participants
- Last Updated